AFP - L3% and DCP as tumor markers in patients with hepatocellular carcinoma (HCC) treated with transarterial chemoembolisation (TACE)

• Conditions: C22.0; Liver cell carcinoma

• Registration Number: DRKS00000812
• Lead Sponsor: KL Freiburg, Med. Klinik II

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2011-05-03
• Study Completion: 2011-09-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 85

Inclusion Criteria

age between 18 and 80
- diagnosis of HCC according the AASLD criteria
- TACE is planned
- resection is impossible

Exclusion Criteria

- liver tumor of unknown origin
- other liver tumors
- TACE is impossible

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
- evaluation of the course of the liver cancer markers AFP, AFP-L3% and DCP after transarterial chemoembolisation. <br>- markers are measured before TACE, 1 month and 3 months after TACE. 3 months after TACE a MRI or CT imaging is performed to evaluate the therapeutic response<br>- analysing the quality of life before and after TACE (3 months after TACE) using the EORTC- QLQ- C30.<br><br>

Secondary Outcome Measures

Name	Time	Method
- long-term survival ( 1-year, 3- year, 5-year- survival)<br>- progression- free – time<br>